Literature DB >> 10782839

Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology.

I Foeldvari1, M Bidde.   

Abstract

OBJECTIVE: The new International League of Associations for Rheumatology (ILAR) classification criteria were proposed to facilitate communication among pediatric rheumatologists. Before they are applied in daily practice they should be clinically validated.
METHODS: We retrospectively applied the proposed criteria on our pediatric rheumatology patient population seen between June 1 and August 31, 1998.
RESULTS: We saw 67 patients with oligoarticular (oJRA), 6 with polyarticular/RF negative (pJRA), and 8 with systemic juvenile rheumatoid arthritis (sJRA), all classified according to American College of Rheumatology criteria, 5 with juvenile psoriatic arthritis (PsA) according to the Vancouver criteria, and 11 with juvenile spondyloarthritis (SP) according to the European Spondylarthropathy Study Group preliminary criteria. Of the 97 patients, 85 could be clearly classified according to the ILAR criteria. Twelve patients (12%) were classified as "other." Six patients could not be classified as "oligo" because of a family history of psoriasis, and did not fulfill the criteria for PsA either. All 6 "other" patients fulfilled criteria for 2 different categories.
CONCLUSION: With this ILAR proposed classification criteria 88% of patients could be classified. In patients classified as "other," the psoriatic trait caused the most difficulty in classification.

Entities:  

Mesh:

Year:  2000        PMID: 10782839

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Imaging of juvenile idiopathic arthritis.

Authors:  Karl Johnson
Journal:  Pediatr Radiol       Date:  2006-06-02

2.  Characteristics of bone marrow cells in 107 patients with juvenile idiopathic arthritis: A retrospective study.

Authors:  Di Zhu; Jihua Zhong; Yiwei Zhang; Fangyuan Chen
Journal:  Exp Ther Med       Date:  2018-08-01       Impact factor: 2.447

Review 3.  Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.

Authors:  Michael W Beresford
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

4.  Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature.

Authors:  Petros E Carvounis; David C Herman; Stephen Cha; James P Burke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-14       Impact factor: 3.117

5.  Kre-Celazine(®) as a viable treatment for juvenile rheumatoid arthritis/juvenile idiopathic arthritis - a pilot study.

Authors:  Jeff Golini; Wendy Lou Jones
Journal:  J Med Food       Date:  2014-06-04       Impact factor: 2.786

Review 6.  Juvenile Idiopathic Arthritis: Diagnosis and Treatment.

Authors:  Gabriella Giancane; Alessandro Consolaro; Stefano Lanni; Sergio Davì; Benedetta Schiappapietra; Angelo Ravelli
Journal:  Rheumatol Ther       Date:  2016-08-12

7.  Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study.

Authors:  Doaa W Nada; Abdelkawy Moghazy; Abdallah El-Sayed Allam; Alessia Alunno; Amira M Ibrahim
Journal:  Front Med (Lausanne)       Date:  2021-05-10

Review 8.  Assessment of the Therapeutic Effect of Total Glucosides of Peony for Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis.

Authors:  Yongsong Cai; Qiling Yuan; Ke Xu; Jialin Zhu; Yuanbo Li; Xiaoqing Wu; Le Yang; Yusheng Qiu; Peng Xu
Journal:  Evid Based Complement Alternat Med       Date:  2016-07-25       Impact factor: 2.629

9.  A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis.

Authors:  Rubén Burgos-Vargas; Shirley M L Tse; Gerd Horneff; Aileen L Pangan; Jasmina Kalabic; Sandra Goss; Kristina Unnebrink; Jaclyn K Anderson
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-11       Impact factor: 4.794

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.